The significance of the YAP downstream CTGF [4] as a potential therapeutic target for liver fibrosis has been demonstrated in several studies employing siRNA-based knockdown of CTGF, which resulted in prevention or inhibition of liver fibrosis in rodents [8, 9]. The gene discussed is YAP1; the disease is Hepatic fibrosis.